AstraZeneca’s (AZN) Buy Rating Reiterated at Kepler Capital Markets
AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by analysts at Kepler Capital Markets in a note issued to investors on Thursday.
Several other brokerages also recently weighed in on AZN. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the company a “buy” rating in a report on Tuesday, September 18th. Jefferies Financial Group reaffirmed a “hold” rating and set a GBX 5,800 ($75.79) price target on shares of AstraZeneca in a report on Friday, October 12th. Deutsche Bank reaffirmed a “buy” rating and set a GBX 6,500 ($84.93) price target on shares of AstraZeneca in a report on Monday, November 12th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca in a report on Monday, October 22nd. Finally, Barclays reaffirmed a “top pick” rating and set a GBX 6,800 ($88.85) price target on shares of AstraZeneca in a report on Friday, November 9th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and an average target price of GBX 5,927.44 ($77.45).
Shares of LON:AZN opened at GBX 6,200 ($81.01) on Thursday. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What is the quiet period?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.